Clinical Study
Radiolabeled Somatostatin Analogues Therapy in Advanced Neuroendocrine Tumors: A Single Centre Experience
Table 5
Results of treatment responses tabulated on the basis of primary tumor site.
| | Site of primitive tumor | CR | PR | SD | PD |
| | GI (19/59) | — | 8/19 (42%) | 9/19 (47%) | 2/19 (11%) | | Pancreas (16/19) | 1/16 (6%) | 5/16 (31%) | 6/16 (38%) | 4/16 (25%) | | Lung (13/59) | — | 8/13 (62%) | 3/13 (23%) | 2/13 (15%) | | Unknown origin (11/59) | — | 3/11 (27%) | 6/11 (55%) | 2/11 (18%) |
|
|
